Wyniki wyszukiwania - AGRO

1

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Assesment of inactivated split influenza vaccine in patients with glomerulonephritis

100%

Brydak L. B., Rajkowski T., Machala M., Weglarska J., Sieniawska M.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

2

Concentrated and purified rabies vaccine for parenteral application in domestic animals

100%

Benisek Z., Suliova J., Svrcek S., Zavadova J., Durove A., Ondrejka R.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

3

Practical use of gE deleted vaccine in IBR control programs: field case reports

100%

Siebert V., Auer S., Kreczdorn D., Strube W., Schmeer N.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

4

Development of paediatric multivalent combined vaccines

100%

Andre F. E.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

5

Influenza virus hemagglutinin as a vaccine antigen produced in bacteria

88%

Saczynska V.

Acta Biochimica Polonica

|

2014

|

tom 61

|

nr 3

6

A universal flu vaccine

88%

Kesik-Brodacka M., Plucienniczak G.

Acta Biochimica Polonica

|

2014

|

tom 61

|

nr 3

7

High-throughput sequencing in vaccine research

88%

Pasik K., Domanska-Blicharz K.

Journal of Veterinary Research

|

2021

|

tom 65

|

nr 2

8

Characterization of rinderpest virus vaccine strains by molecular biology techniques

88%

Ayanot P. K., Kolosov S. N., Lomakin A. I., Starov S. K., Drygin V. V., Gusev A. A.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

9

Study on immunity duration in polecats inoculated with inactivated vaccine against canine distemper

88%

Ultmelidze G. O., Starov S. K., Evseev A. M., Sarbasov A. S., Gerasimova N. I., Gusev A. A., Markina M. I.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

10

Novel approaches for developing vaccines

88%

Babiuk L. A.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

11

Bacterial ghosts as multifunctional vaccine particles

88%

Lubitz W.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

12

Development of vaccinia virus recombinants expressing various glycoproteins of varicella-zoster virus

88%

Nemeckova S., Maresova L., Ludvikova V., Hainz P., Kutinova L.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

13

An attempt to evaluate the efficacy of vaccines against pasteurellosis in rabbits

88%

Borkowska-Opacka B., Rutkowska-Jurga I., Truszczynski M., Kozaczynski W.

Bulletin of the Veterinary Institute in Puławy

|

1996

|

tom 40

|

nr 1

The goal of the studies was to evaluate the protective value of vaccines against pasteurellosis in rabbits. The vaccines comprised antigens to serotypes 3 and 12 of Pasteurella multocida with two different adjuvants: emulsigen and aluminium hydroxide gel. The two vaccines given subcutaneusly either once or twice at a dose of 1 ml protected rabbits markedly against intranasal infection with the virulent strains of examined serotypes. A substantial efficacy of these vaccines was supported by the occurrence of specific precipitins against somatic antigens of serotypes 3 and 12 present in the sera of immunised rabbits even 5 weeks after vaccination

14

Virus vaccine against sheep pox prepared on the passaged culture of kids' gonads

88%

Diev V. I., Sokholov L. N.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

15

Rabies incidence and night counting of foxes in France

88%

Aubert M., Vuillaume P.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

16

New generation adjuvants for subunit vaccines and their potential use in active immunotherapy

88%

Garcon N.

Bulletin of the Veterinary Institute in Puławy

|

1998

|

tom 42

|

nr 1

17

Bluetongue vaccines in Europe

75%

Niedbalski W.

Polish Journal of Veterinary Sciences

|

2011

|

tom 14

|

nr 2

The article reviews the history, present status and the future of BT vaccines in Europe. So far, an attenuated (modified live viruses, MLV) and inactivated virus vaccines against BT were developed and used in the field. Moreover, the virus-like particles (VLPs) produced from recombinant baculovirus, and live recombinant vaccinia or canarypox virus-vectored vaccines were tested in the laboratory. The main aims of BT vaccination strategy are: to prevent clinical disease, to reduce the spread of the BTV in the environment and to protect movement of susceptible animals between affected and free zones. Actually, all of the most recent European BT vaccination campaigns have used exclusively inactivated vaccines. The use of inactivated vaccines avoid risk associated with the use of live-attenuated vaccines, such as reversion to virulence, reassortment of genes with field strain, teratogenicity and insufficient attenuation leading to clinical disease. The mass vaccinations of all susceptible animals are the most efficient veterinary method to fight against BT and successful control of disease. The vaccination of livestock has had a major role in reducing BTV circulation and even in eradicating the virus from most areas of Europe.

18

Identification of CD4plus T cell epitopes from Staphylococcus aureus secretome using immunoinformatic prediction and molecular docking

75%

Francis D., Kumar A., Chittalakkottu S.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2021

|

tom 102

|

nr 1

19

Modern aspects on Shigella pathogenecity and vaccine development - a review

75%

Pal P.

International Letters of Natural Sciences

|

2014

|

tom 12

|

nr 1

Shigella species are intracytosolic Gram-negative invasive enteropathogenic bacteria, causing the rupture, invasion and inflammatory destruction of the human colonic epithelium. They utilize the host cytoskeletal components to form propulsive actin tails. The so-called invasive phenotype of Shigella is linked to expression of a type III secretory system (TTSS) injecting effector proteins into the epithelial cell membrane and cytoplasm, thereby inducing local but massive changes in the cell cytoskeleton that lead to bacterial internalization into non-phagocytic intestinal epithelial cells. The molecular and cellular bases of this invasive phenotype essentially encompass crossing of the epithelial lining, apoptotic killing of macrophages, entry into epithelial cells, and escape into the cytoplasm, followed by cell-to-cell spread. Intracellular colonization is likely to protect the micro-organisms from killing by humoral and cellular effectors of the innate immune response. Concurrently, the capacity of Shigella to reprogram invaded epithelial cells to produce proinflammatory mediators plays a major role in the strong inflammatory profile of the disease. This profile is likely to impact on the nature and quality of the adaptive response, which is dominated by humoral protection at the mucosal level. In recent years, a large amount of information has been generated regarding the host, pathogen and environmental factors that impact the pathogenesis of shigellosis at the cellular and molecular level. This review summarizes what is currently known about Shigella, detailing those factors that contribute to pathogenesis and examining the current progress in the development of a vaccine.

20

Attempts at the development of a recombinant African swine fever virus strain with abrogated EP402R, 9GL, and A238L gene structure using the CRISPR/Cas9 system

75%

Wozniakowski G., Mazur-Panasiuk N., Walczak M., Juszkiewicz M., Frant M., Niemczuk K.

Journal of Veterinary Research

|

2020

|

tom 64

|

nr 2

Ograniczanie wyników